home All News open_in_new Full Article

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE

Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily treatment-experienced people with multidrug resistant HIV MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the […]



Theratechnologies presented PROMISE-US trial data at CROI 2025, demonstrating ibalizumab's efficacy and safety in reducing HIV RNA to undetectable levels in heavily treatment-experienced patients with multidrug-resistant HIV. The PROMISE-US registry study showed that patients treated with ibalizumab achieved similar rates of undetectable viral load as those on non-ibalizumab regimens, despite more severe HIV disease at baseline.

today 48 h. ago attach_file Other

attach_file Economics
attach_file Economics
attach_file Society
attach_file Economics
attach_file Technology
attach_file Events
attach_file Other
attach_file Transport
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Other
attach_file Transport
attach_file Other
attach_file Transport
attach_file Other
attach_file Economics
attach_file Economics
attach_file Politics


ID: 948573956
Add Watch Country

arrow_drop_down